Project Grant R21AI190341
Award Date
7/2/25
Completion Date
6/30/27
Dollars Obligated
$262K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The Stanford University received a $337,147 Project Grant award from the National Institute of Allergy and Infectious Diseases to develop an immunization against Pseudomonas aeruginosa infection. The grant supports research to evaluate the effectiveness of antibodies against bacteriophage PF in promoting phagocytosis and clearance of P. aeruginosa, determining the ability of anti-PF antibodies to protect against multiple clinical strains, and examining the presence of anti-PF antibodies in human...
This $151,040 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the regulatory role of the small regulatory RNA BECO on essential virulence factors in the pathogen Pseudomonas aeruginosa. The research aims to determine how BECO controls the expression of the Type III Secretion System and pyochelin biosynthesis genes, which are critical for P....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital to develop targeted vaccine candidates against nontuberculous mycobacterial (NTM) infections. The project aims to evaluate the efficacy of two NTM vaccine candidates - an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine - in mouse models. Key research activities include screening...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $404,539 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Rochester General Hospital. The grant will fund the development and evaluation of a novel Haemophilus influenzae lipoprotein fusion vaccine and vaccine platform. Key research objectives include assessing the immunogenicity and protective efficacy of lipidated and fusion protein constructs against nasopharyngeal...
This Project Grant award of $868,776.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to: Identify the direct regulatory targets of the RNA-binding protein PhaF under standard lab conditions, infection-relevant conditions, and in clinical isolates to...
This $234,586 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support the synthesis and evaluation of glycoconjugate vaccine candidates to prevent Acinetobacter baumannii infection. The key goals are to chemically synthesize A. baumannii glycans, conjugate them to carrier proteins, and assess the immunogenicity and protective effects of the resulting glycoconjugates in mouse...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, provides $430,760 to the University of Pittsburgh to conduct research on improving host defense against the deadly Gram-negative bacterium, Pseudomonas aeruginosa. The key objectives are to: 1) Determine the role of the CXCR4 chemokine receptor and galectin-3 protein in the protective function of lung...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), aims to develop a novel vaccine candidate that stimulates immune protection against multi-drug resistant Acinetobacter baumannii (MDR-AB). The $288,360 award to Biological Mimetics, Inc., a biotechnology firm in Frederick, Maryland, supports a Phase I project to: (1) identify and characterize key immunogenic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...